Sleep and Alzheimer's disease.
Study Goal
The researchers aimed to explore the potential of melatonin combined with bright light treatment in managing sleep disorders in Alzheimer's disease patients.
Results Summary
The study suggests that melatonin combined with bright light treatment may be promising for managing sleep disorders in Alzheimer's disease, though specific efficacy data are not detailed. Sleep disorders in AD patients include fragmentation, reduced duration, and circadian disruptions.
Population
Patients with Alzheimer's disease experiencing sleep disorders.
Effective Dosage
Not specified
Duration
Not specified
Interactions
None mentioned
| Intervention | Direction | Endpoint | Population | Dosage | Impact | Claim # |
|---|---|---|---|---|---|---|
melatonin and bright light treatment | decrease | sleep disorders in Alzheimer's disease | patients with Alzheimer's disease | - | seems to be promising | #1 |
Sleep disorders are frequent in Alzheimer's disease (AD), with a significant impact on patients and caregivers and a major risk factor for early institutionalization. Micro-architectural sleep alterations, nocturnal sleep fragmentation, decrease in nocturnal sleep duration, diurnal napping and even inversion of the sleep-wake cycle are the main disorders observed in patients with AD. Experimental and epidemiological evidence for a close reciprocal interaction between cognitive decline and sleep alterations is growing. Management of sleep disorders in AD is pre-eminently behavioral. Association of melatonin and bright light treatment seems to be promising as well. The presence of sleep complaints, especially excessive somnolence in demented patients, should draw attention to possible associated sleep pathologies such as sleep apnea syndrome or restless legs syndrome.